

Indonesia

Financial Report



20
FIRST QUARTER
26



Contents

Financial Review	3
<hr/>	
Consolidated Financial Statements	17
<hr/>	
Disclaimers	24

Financial Review

Idorsia's key numbers

Profit and loss

(in CHF millions, except EPS)	US GAAP		First quarter Non-GAAP	
	2026	2025	2026	2025
Net revenue				
Product sales	46	27	46	27
Contract revenue – royalties	4	1	-	-
Contract revenue – others	7	32	7	32
Operating expenses				
Cost of sales	(8)	(2)	(8)	(2)
Research and development	(24)	(27)	(21)	(25)
Selling, general and administrative	(52)	(54)	(48)	(51)
Net results				
Operating income (loss)	(26)	67	(24)	(17)
Net income (loss)	(46)	63	(36)	(25)
Basic EPS	(0.18)	0.33	(0.14)	(0.13)
Diluted EPS	(0.18)	0.23	(0.14)	(0.13)

Liquidity

(in CHF millions)	Mar 31, 2026	Dec 31, 2025
Liquidity		
Cash and cash equivalents	95	89
Total liquidity	95	89

Shares

(in millions)	Mar 31, 2026	Dec 31, 2025
Share count		
Issued common shares	254.0	250.7
Equity derivatives	45.2	47.8
Equity instruments	18.0	15.2
Total potential issued shares	317.1	313.7

Indebtedness

(in CHF millions)	Mar 31, 2026	Mar 31, 2026	Dec 31, 2025	Dec 31, 2025
	Book value	Nominal amount	Book value	Nominal amount
Indebtedness				
Convertible loan	335	335	335	335
Debt notes*	766	774	753	762
Convertible bonds	49	49	49	49
New money facility	60	113	18	78
Other financial debt	185	186	187	189
Total indebtedness	1,395	1,457	1,342	1,413

* Debt notes issued by Idorsia Investments SARL.

Revenue

Revenue

(in CHF millions)	First quarter	
	2026	2025
Revenue		
Product sales	46	27
Contract revenue – others	7	32
Non-GAAP revenue	53	58
Contract revenue – royalties	0	1
Contract revenue – milestones	4	-
US GAAP revenue	57	59

Non-GAAP revenue comprised:

Product sales of QUVIVIQ™ (daridorexant), with net sales of CHF 44 m in France, US, Germany, UK, Switzerland, Canada, Italy, Spain, Austria, Sweden and Finland, as well as sales to partners mainly in the Asia-Pacific-Region of CHF 2 m.

Contract revenue – others, reflecting an exclusivity fee of USD 8 m (CHF 6 m) received from EMS S.A and USD 0.5 m (CHF 0.4 m) received from Pharmalink for the commercialization and distribution of QUVIVIQ™ (daridorexant) in Latin America and across the United Arab Emirates (UAE), Kuwait, Qatar, Oman, and Bahrain respectively.

US GAAP revenue comprised Non-GAAP revenue and Contract revenue, reflecting non-cash revenue recognized under the R-Bridge royalty monetization agreement.

Operating expenses

Operating expenses

(in CHF millions)	First quarter	
	2026	2025
Operating expenses		
Cost of sales	8	2
Research	7	11
Development	14	13
Selling	35	35
General and administrative	14	16
Non-GAAP operating expenses	78	78
Depreciation and amortization	4	4
Share-based compensation	3	2
Restructuring charges	(0)	1
Effect of the Viatris/Sosei Deal	-	(90)
Other operating expenses	6	(83)
US GAAP operating expenses	84	(5)

US GAAP operating expenses of CHF 84 m comprised of Non-GAAP operating expenses (CHF 78 m), depreciation and amortization (CHF 4 m) and share-based compensation (CHF 3 m).

Cost of sales

(in CHF millions)	First quarter	
	2026	2025
Cost of sales		
Cost of goods sold	8	2
US GAAP cost of sales	8	2

Cost of sales of CHF 8 m comprised the cost of goods sold (CHF 8 m).

Research and development (“R&D”) expenses

(in CHF millions)	First quarter	
	2026	2025
R&D expenses		
Research	7	11
Development	14	13
Non-GAAP R&D expenses	21	25
Depreciation and amortization	2	2
Share-based compensation	1	1
US GAAP R&D expenses	24	27

Non-GAAP research expenses of CHF 7 m comprised of preclinical activities (CHF 3 m), biology (CHF 2 m) and chemistry (CHF 2m).

Non-GAAP development expenses of CHF 14 m comprised of CHF 9 m for clinical activities (including CHF 4 m study costs, mainly driven by late stage studies for daridorexant and lucerastat) and CHF 5 m for chemical and pharmaceutical development activities (including CHF 1 m for drug substance and drug product).

Selling, general and administrative (“SG&A”) expenses

(in CHF millions)	First quarter	
	2026	2025
SG&A expenses		
Selling	35	35
General and administrative	14	16
Non-GAAP SG&A expenses	49	51
Depreciation and amortization	2	2
Share-based compensation	2	1
US GAAP SG&A expenses	53	54

Non-GAAP SG&A expenses of CHF 49 m comprised of commercial activities (CHF 35 m), information systems (CHF 6 m) and other support functions (CHF 8 m).

Operating results

Operating results

(in CHF millions)	First quarter	
	2026	2025
Operating results		
Revenues	53	58
Operating expenses	(78)	(78)
Other income	1	3
Non-GAAP operating income (loss)	(24)	(17)
Operating results		
Revenues	57	59
Operating expenses	(84)	5
Other income	1	3
US GAAP operating income (loss)	(26)	67

US GAAP operating loss of CHF 26 m mainly comprised of Non-GAAP operating loss (CHF 24 m), depreciation and amortization (CHF 4 m), share-based compensation (CHF 3 m), as well as non-cash royalty and sales milestone revenue recognized under the R-Bridge royalty monetization agreement (CHF 4).

Financial results

Financial results

(in CHF millions)	First quarter	
	2026	2025
Financial results		
Interest income (expense), net	(11)	(5)
Other financial income (expense), net	(0)	(2)
Non-GAAP financial income (expense)	(12)	(8)
Interest income (expense), net	(8)	(2)
Gain (loss) on securities	-	7
Other financial income (expense), net	0	-
US GAAP financial income (expense)	(20)	(3)

US GAAP financial expense of CHF 20 m included:

- Non-GAAP financial expense of CHF 12 m including interests on Debt notes (CHF 8m), interests on the New Money Facility loan (CHF 1 m), interest on leases (CHF 2 m)
- Non-cash interest expense (Total CHF 8 m) related to interest of royalty monetization (CHF 2 m) and accretion on the New Money Facility loan (CHF 6 m).

Income tax

Income tax

(in CHF millions)	First quarter	
	2026	2025
Income tax		
Income tax benefit (expense)	0	(0)
Non-GAAP tax benefit (expense)	0	(0)
Other tax benefit (expense)	0	0
US GAAP income tax benefit (expense)	0	(0)

US GAAP income tax expense mainly included the Non-GAAP tax expense of foreign affiliates (CHF 1 m) and income tax benefit from deferred taxes (CHF 1 m).

Net results, EPS and shares

Net results

(in CHF millions)	First quarter	
	2026	2025
Non-GAAP operating income (loss)	(24)	(17)
Financial income (expense)	(12)	(8)
Income tax benefit (expense)	0	(0)
Non-GAAP net income (loss)	(36)	(25)
US GAAP operating income (loss)	(26)	67
Financial income (expense)	(20)	(3)
Income tax benefit (expense)	0	(0)
US GAAP net income (loss)	(46)	63

US GAAP net loss of CHF 46 m comprised of Non-GAAP net loss (CHF 36 m), depreciation and amortization (CHF 4 m), share-based compensation (CHF 3 m), accretion expenses (CHF 6 m) and interest expense recognized under the R-Bridge royalty monetization agreement (CHF 2 m), offset by non-cash royalty and sales milestone revenue recognized under the R-Bridge royalty monetization agreement (CHF 4 m).

Shares

(in millions)	Issued	Potentially dilutive equity instruments		Total potential issued shares
		Derivatives	Awards	
Dec 31, 2025	250.7	47.8	15.2	313.7
Issued	2.6	-	4.1	6.7
Vested	0.6	-	(0.6)	-
Exercised	-	(2.6)	-	(2.6)
Forfeited	-	-	(0.1)	(0.1)
Expired	-	-	(0.5)	(0.5)
Mar 31, 2026	254.0	45.2	18.0	317.2

Issued shares increased to 254 million mainly due to exercise of warrants and vesting of equity awards. As at March 31, 2026, issued shares include Nil treasury shares held by the Group.

Equity awards of 18 million comprised of 8.4 million share options with a weighted average strike price of CHF 10.32 granted to eligible employees and 9.6 million unvested share units granted to eligible employees.

Earnings per share (EPS)

(in CHF millions, unless otherwise indicated)	First quarter	
	2026	2025
Non-GAAP net income (loss)	(36)	(25)
Weighted-average number of basic shares (in millions)	253	189
Non-GAAP basic EPS (in CHF)	(0.14)	(0.13)
Weighted-average number of dilutive shares (in millions)	253	189
Non-GAAP diluted EPS (in CHF)	(0.14)	(0.13)
US GAAP net income (loss)	(46)	63
Weighted-average number of basic shares (in millions)	253	189
US GAAP basic EPS (in CHF)	(0.18)	0.33
Weighted-average number of dilutive shares (in millions)	253	271
US GAAP diluted EPS (in CHF)	(0.18)	0.23

Cash flow and liquidity

Operating cash flow

(in CHF millions)	First quarter	
	2026	2025
Operating cash flow		
US GAAP net income (loss)	(46)	63
Deferred contract revenue and accrued income	-	(1)
Deferred taxes	(1)	0
Depreciation and amortization	4	4
Non-cash royalty monetization interest	2	2
Accretion of borrowings	7	-
Adjustments for interests capitalized on Debt notes	13	-
Fair value changes on securities	-	(7)
Fair value changes on derivative liabilities	0	-
Share-based compensation	3	2
Gain from Viatrix deal	-	(90)
Net outflows from operations	(18)	(25)
Net change in receivables	(13)	3
Net change in inventories	4	(0)
Net change in trade and other payables	5	8
Net change in other operating assets and liabilities	(3)	(47)
Change in working capital	(8)	(36)
Operating cash flow	(26)	(61)

Net outflows from operations of CHF 18 m were mainly driven by the Non-GAAP operating loss (CHF 24 m).

Net cash outflows in working capital of CHF 8 m were mainly driven by inventory decrease (CHF 4 m), a increase in trade and other payables (CHF 5 m), and an increase in receivables (CHF 13 m).

Cash flow

(in CHF millions)	First quarter	
	2026	2025
Cash flow		
Operating cash flow	(26)	(61)
Acquisition/Sale of tangible, intangible and other assets	(2)	(0)
Free cash flow	(28)	(61)
Issuance and sale of shares	-	5
Proceeds from exercise of warrants	4	-
Proceeds from borrowings	35	-
Payment of debt issuance costs	(0)	(6)
Proceeds from sale of marketable securities	-	7
Repayments of borrowings	(4)	-
Other items	(0)	(1)
Cash flow¹	6	(55)

¹ Cash flow is reconciled with the liquidity movements shown below.

The positive cash inflow of CHF 6m was primarily driven by the additional withdrawal of the New Money Facility Loan (CHF 35 m) and proceeds from exercise of warrants (CHF 4 m), offset by operating cash outflow (CHF 26 m), acquisition and sale of tangible and intangible assets, net (CHF 2 m) and repayments of borrowings reflecting contract revenue recognized under the R-Bridge royalty monetization agreement (CHF 4 m).

Liquidity

(in CHF millions)	Liquidity
Liquidity Dec 31, 2025	89
Liquidity movements Q1	6
Liquidity Mar 31, 2026	95

As of March 31, 2026, liquidity of CHF 95 m, consisting of cash and cash equivalents, was mainly held in Swiss francs (CHF 56 m), US dollars (equivalent of CHF 11 m) and Euro (equivalent of CHF 25 m).

Balance sheet

Balance sheet

(in CHF millions)	Mar 31, 2026	Dec 31, 2025
Assets		
Liquidity ¹	95	89
Tangible assets	187	191
Other assets	199	186
Total assets	480	465
Liabilities and equity		
Financial debt	1,395	1,342
Other liabilities	262	260
Total liabilities	1,657	1,602
Total equity	(1,177)	(1,137)
Total liabilities and equity	480	465

¹ Liquidity includes cash and cash equivalents

Tangible assets of CHF 187 m comprised real-estate (CHF 77 m) and right-of-use assets (CHF 111 m).

Other assets of CHF 199 m comprised receivables (CHF 55 m), inventories (CHF 78 m), intangible assets (CHF 30 m) and other assets (CHF 21 m).

Financial debt of CHF 1,395 m comprised the convertible loan (CHF 335 m), debt notes (CHF 766 m), convertible bonds (CHF 49 m), a term loan (CHF 60 m), a sale and leaseback transaction (CHF 162 m) and a royalty monetization liability (CHF 23 m).

Other liabilities of CHF 262 m included current and noncurrent liabilities. Current liabilities of CHF 141 m mainly comprised accrued expenses (CHF 71 m), payables (CHF 25 m), sales related liabilities (CHF 37 m) and a short-term lease liability (CHF 7 m). Noncurrent liabilities of CHF 121 m comprised a long-term lease liability (CHF 102 m), sales related long-term liability (CHF 13 m) and accrued expenses (CHF 6 m).

Reconciliation of US GAAP to non-GAAP results

Reconciliation of US GAAP to non-GAAP results for the three months ended March 31, 2026

(in CHF millions, unless otherwise indicated)	US GAAP results	Depreciation, amortization	Share-based compensation	Royalty monetization	Other items	Non-GAAP results
Net revenue						
Product sales	46	-	-	-	-	46
Contract revenue – royalties	0	-	-	(0)	-	-
Contract revenue – milestones	4	-	-	(4)	-	0
Contract revenue – others	7	-	-	-	-	7
Total net revenue	57	-	-	(4)	-	53
Operating expenses						
Cost of sales	(8)	-	-	-	-	(8)
Research and development	(24)	2	1	-	-	(21)
Selling, general and administrative	(51)	0	2	-	-	(49)
Amortization of intangible assets	(1)	1	-	-	-	-
Restructuring charges	0	-	-	-	(0)	-
Total operating expenses	(84)	4	3	-	(0)	(78)
Other income	1	-	-	-	-	1
Operating results	(26)	4	3	(4)	(0)	(24)
Total financial income (expense)	(20)	-	-	2	6	(12)
Income before income tax benefit (expense)	(46)	4	3	(2)	6	(36)
Income tax benefit (expense)	0	(0)	(0)	-	-	0
Net income (loss)	(46)	4	3	(2)	6	(36)
Basic net income (loss) per share (CHF)	(0.18)	0.01	0.01	(0.01)	0.02	(0.14)
Weighted-average number of basic shares (in millions)	253	-	-	-	-	253
Diluted net income (loss) per share (CHF)	(0.18)	0.01	0.01	(0.01)	0.02	(0.14)
Weighted-average number of dilutive shares (in millions)	253	-	-	-	-	253

Interim Consolidated Financial Statements

Interim Consolidated Income Statement

(in CHF thousands, except per share amounts)	Three months ended March 31,	
	2026	2025
	(unaudited)	(unaudited)
Net revenue		
Product sales	45,974	26,567
Contract revenue	11,420	32,316
Total net revenue	57,394	58,883
Operating (expenses)¹		
Cost of sales	(8,063)	(2,441)
Research and development	(23,747)	(27,452)
Selling, general and administrative	(51,458)	(52,398)
Amortization of intangible assets	(1,307)	(1,630)
Restructuring charges	143	(646)
Gains on sale of disposal group	-	89,550
Total operating (expenses)	(84,430)	4,983
Other income	653	2,798
Operating income (loss)	(26,384)	66,665
Interest income (expense), net	(19,346)	(7,542)
Other financial income (expense), net	(453)	4,387
Total financial income (expense)	(19,799)	(3,154)
Income (loss) before income tax benefit (expense)	(46,183)	63,510
Income tax benefit (expense)	486	(393)
Net income (loss)	(45,696)	63,118
Basic net income (loss) per share attributable to Idorsia's shareholders	(0.18)	0.33
Weighted-average number of common shares (in thousands)	252,657	188,889
Diluted net income (loss) per share attributable to Idorsia's shareholders	(0.18)	0.23
Weighted-average number of common shares (in thousands)	252,657	270,760
¹ Includes share-based compensation as follows:		
Research and development	671	754
Selling, general and administrative	2,092	1,178
Total share-based compensation	2,763	1,932

Interim Consolidated Statement of Comprehensive Income

(in CHF thousands)	Three months ended March 31,	
	2026	2025
	(unaudited)	(unaudited)
Net income (loss)	(45,696)	63,118
Other comprehensive income (loss), net of tax:		
Foreign currency translation adjustments	82	35
Change of unrecognized components of net periodic benefit costs	(366)	(376)
Other comprehensive income (loss), net of tax	(283)	(341)
Comprehensive income (loss)	(45,980)	62,777

Interim Consolidated Balance Sheet (1/2)

(in CHF thousands, except number of shares)	Mar 31, 2026	Dec 31, 2025
	(unaudited)	(audited)
ASSETS		
Current assets		
Cash and cash equivalents	94,697	88,544
Trade and other receivables, net	55,258	42,348
Inventories	78,298	82,051
Other current assets	11,308	10,864
Total current assets	239,561	223,807
Noncurrent assets		
Long-term deposits	2	2
Property, plant and equipment, net	76,529	78,832
Right-of-use assets	110,535	112,031
Intangible assets, net	30,398	29,591
Pension asset	13,274	12,109
Deferred tax asset	1,500	771
Other noncurrent assets	8,659	8,735
Total noncurrent assets	240,897	242,071
TOTAL ASSETS	480,458	465,878

Interim Consolidated Balance Sheet (2/2)

(in CHF thousands, except number of shares)	Mar 31, 2026 (unaudited)	Dec 31, 2025 (audited)
LIABILITIES		
Current liabilities		
Trade and other payables	23,383	17,455
Payables and accrued payables to related parties	2,034	1,410
Deferred revenue	48	48
Lease liability	6,920	7,590
Sales related liabilities	36,924	35,484
Accrued expenses	71,274	87,653
Provisions	306	727
Royalty monetization liability	8,812	10,493
Total current liabilities	149,701	160,860
Noncurrent liabilities		
Convertible loan	334,575	334,575
Convertible bonds	49,324	49,324
Debt notes	765,824	753,097
Other financial liabilities	162,664	162,614
Term loan	60,381	17,934
Lease liability	102,531	104,625
Sales related liabilities	12,397	–
Deferred tax liability	1	635
Derivative financial liabilities ¹	1,142	1,132
Other noncurrent liabilities	5,041	4,267
Royalty monetization liability	13,447	13,988
Total noncurrent liabilities	1,507,327	1,442,191
Total liabilities	1,657,027	1,603,051
EQUITY		
Idorsia's shareholders' equity		
Common shares (par value CHF 0.05 per share, issued and outstanding 253,983,453 and 250,736,034 as of March 31, 2026 and December 31, 2025 respectively; total number of authorized shares, including issued, conditional and upper end of capital range, 449,470,174 as of March 31, 2026 and 449,470,174 as of December 31, 2025 respectively)	12,699	12,537
Additional paid-in capital	2,365,234	2,358,812
Accumulated profit (loss)	(3,564,168)	(3,518,471)
Accumulated other comprehensive income (loss)	9,666	9,949
Total Idorsia's shareholders' equity	(1,176,569)	(1,137,173)
TOTAL LIABILITIES AND EQUITY	480,458	465,878

¹ Previously presented within "Other noncurrent liabilities".

Interim Consolidated Statement of Cash Flows (1/2)

(in CHF thousands)	Three months ended March 31,	
	2026	2025
	(unaudited)	(unaudited)
Cash flow from operating activities		
Net income (loss)	(45,696)	63,118
Adjustments to reconcile net income (loss) to net cash provided from operating activities:		
Depreciation and amortization	3,757	4,327
Non-cash royalty monetization interest	1,990	2,194
Share-based compensation	2,763	1,932
Accretion of borrowings	7,302	244
Adjustments for interest capitalized on debt notes	1,396	-
Fair value changes on securities	-	(6,847)
Fair value changes on derivative liabilities	145	-
Release of deferred revenue and accrued income	0	(600)
Gain on disposals of assets	-	(89,550)
Amortization of debt issuance costs	225	-
Deferred taxes	(1,359)	61
Changes in operating assets and liabilities:		
Trade and other receivables	(13,348)	3,287
Prepayments	(2,036)	(3,848)
Inventories	3,747	(36)
Trade and other payables	4,544	7,703
Accrued expenses	(286)	(44,088)
Provisions	(394)	(3,007)
Changes in other operating cash flow items	(487)	4,437
Other non-cash adjustment for interest capitalized on Debt notes	11,107	-
Net cash flow provided by (used in) operating activities	(26,630)	(60,674)
Cash flow from investing activities		
Proceeds from sales of marketable securities	-	7,037
Purchase of property, plant and equipment	(212)	(84)
Purchase of intangible assets	(1,410)	(98)
Net cash flow provided by (used in) investing activities	(1,622)	6,855

Interim Consolidated Statement of Cash Flows (2/2)

(in CHF thousands)	Three months ended March 31,	
	2026	2025
	(unaudited)	(unaudited)
Cash flow from financing activities		
Issuance of new shares, net	-	5,000
Proceeds from exercise of warrants	3,821	-
Proceeds from borrowings	35,000	-
Repayments of borrowings	(4,388)	(576)
Payment of debt issuance costs	(0)	(6,076)
Net cash flow provided by (used in) financing activities	34,432	(1,652)
Net effect of exchange rates on cash and cash equivalents	(26)	(227)
Net change in cash and cash equivalents	6,154	(55,698)
Cash and cash equivalents at beginning of period	88,544	106,376
Cash and cash equivalents at end of period	94,697	50,678

Interim Consolidated Statement of Changes in Equity

(in CHF thousands, except number of shares)	Idorsia's shareholders						Total equity
	Common shares			Accum. profit (loss)	Treasury shares	Accum. other comprehensive income (loss)	
	Shares	Amount	Additional paid-in capital				
At January 1, 2025	189,743,556	9,487	2,182,337	(3,406,776)	(52)	2,859	(1,212,145)
Comprehensive income (loss):							
Net income (loss)				63,118			63,118
Other comprehensive income (loss)						(341)	(341)
Comprehensive income (loss)							62,777
Share-based compensation transactions	544,607	27	1,359				1,387
Transactions in treasury shares	35,000,000	1,750	15,100		(1,050)		15,800
At March 31, 2025 (unaudited)	225,288,163	11,264	2,198,796	(3,343,658)	(1,102)	2,518	(1,132,182)
Comprehensive income (loss):							
Net income (loss)				(174,813)			(174,813)
Other comprehensive income (loss)						7,432	7,432
Comprehensive income (loss)							(167,381)
Share-based compensation transactions	1,922,221	96	4,215				4,311
Issuance and exercises of warrants	10,645,944	532	47,119				47,651
Issuance of new shares	12,879,706	644	49,049				49,693
Transactions in treasury shares			59,633		1,102		60,735
At December 31, 2025 (audited)	250,736,034	12,537	2,358,812	(3,518,472)	-	9,950	(1,137,173)
Comprehensive income (loss):							
Net income (loss)				(45,696)			(45,696)
Other comprehensive income (loss)						(283)	(283)
Comprehensive income (loss)							(45,980)
Share-based compensation transactions	679,291	34	2,729				2,763
Issuance and exercises of warrants	2,568,128	128	3,692				3,821
At March 31, 2026 (unaudited)	253,983,453	12,699	2,365,233	(3,564,168)	-	9,666	(1,176,569)

Disclaimers

Forward-looking statements


The information in this Report contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's or Group's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's or Group's existing portfolio. Such statements reflect the current views of the company or the Group with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company or the Group to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Financial Report

Idorsia measures and reports its non-GAAP operating performance, which management believes more accurately reflects the underlying business performance. The Group believes that these non-GAAP financial measurements provide useful supplementary information for investors. These non-GAAP measures are reported in addition to, not as a substitute for, US GAAP financial performance.

Rounding differences may occur

nm = not meaningful.



Curious to learn more?
Reach out to us.

Investor Relations
Idorsia Ltd
Hegenheimermattweg 91
4123 Allschwil
Switzerland

Phone +41 58 844 10 10
investor.relations@idorsia.com
www.idorsia.com

© Idorsia Pharmaceuticals Ltd 2026

All trademarks are legally protected.